Success Metrics

Clinical Success Rate
88.3%

Based on 121 completed trials

Completion Rate
88%(121/137)
Active Trials
30(15%)
Results Posted
51%(62 trials)
Terminated
16(8%)

Phase Distribution

Ph not_applicable
10
5%
Ph phase_2
32
16%
Ph phase_4
40
20%
Ph phase_3
44
22%
Ph early_phase_1
1
1%
Ph phase_1
21
11%

Phase Distribution

22

Early Stage

32

Mid Stage

84

Late Stage

Phase Distribution148 total trials
Early Phase 1First-in-human
1(0.7%)
Phase 1Safety & dosage
21(14.2%)
Phase 2Efficacy & side effects
32(21.6%)
Phase 3Large-scale testing
44(29.7%)
Phase 4Post-market surveillance
40(27.0%)
N/ANon-phased studies
10(6.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.0%

121 of 144 finished

Non-Completion Rate

16.0%

23 ended early

Currently Active

30

trials recruiting

Total Trials

199

all time

Status Distribution
Active(39)
Completed(121)
Terminated(23)
Other(16)

Detailed Status

Completed121
Recruiting25
unknown16
Terminated16
Not yet recruiting9
Withdrawn7

Development Timeline

Analytics

Development Status

Total Trials
199
Active
30
Success Rate
88.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.7%)
Phase 121 (14.2%)
Phase 232 (21.6%)
Phase 344 (29.7%)
Phase 440 (27.0%)
N/A10 (6.8%)

Trials by Status

unknown168%
completed12161%
active_not_recruiting53%
not_yet_recruiting95%
recruiting2513%
terminated168%
withdrawn74%

Recent Activity

Clinical Trials (199)

Showing 20 of 199 trialsScroll for more
NCT07753200Phase 4

Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease

Recruiting
NCT07493304Phase 3

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Recruiting
NCT07747948

Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation

Not Yet Recruiting
NCT07175428Phase 2

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Recruiting
NCT04618913

Anticoagulation in Patients With Venous Thromboembolism and Cancer

Completed
NCT07716332Not Applicable

Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis

Not Yet Recruiting
NCT07713875Phase 4

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

Not Yet Recruiting
NCT07709780Phase 3

Apixaban Versus Warfarin for Left Ventricular Thrombus

Recruiting
NCT07699796Phase 4

Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

Completed
NCT07015905Phase 3

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Recruiting
NCT07312851Phase 1

A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants

Completed
NCT03448783

Bariatric Surgery and Pharmacokinetics of Apixaban

Recruiting
NCT05757869Phase 3

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Active Not Recruiting
NCT06370273Phase 3

Thromboprophylaxis in Lower Limb Immobilisation

Recruiting
NCT05038228

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

Completed
NCT03266783Phase 4

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Completed
NCT06243510Not Applicable

Comparison of Apixaban Versus Enoxaparin

Completed
NCT06953726Phase 4

Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

Recruiting
NCT05035277Phase 3

AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

Completed
NCT06486792Phase 4

Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
199